Israeli Start-Up Raises $15M for U.S. Pivotal Clinical Trial

Regentis Biomaterials has raised $15 million in Series D funding for its hydrogel based resorbable implant for cartilage injuries.

The investment will be used primarily for conducting a pivotal clinical trial on GelrinC in the U.S. to obtain FDA marketing approval, according to Alastair Clemow, Regentis Biomaterial’s CEO.

The investment was led by Haisco Pharmaceutical Group and was joined by existing investors, including Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and both the Technion Research & Development Foundation and the Technion Innovation Opportunities Fund. — Jonathon Shacat